FMS Kinase Inhibitors: Current Status and Future Prospects

Title
FMS Kinase Inhibitors: Current Status and Future Prospects
Authors
모하메드엘가말하난유경호오창현
Keywords
FMS; CSF-1; CSF-1R; IL-34; monoclonal antibodies; FMS kinase inhibitors
Issue Date
2013-05
Publisher
Medicinal research reviews
Citation
VOL 33, NO 3, 599-636
Abstract
FMS, first discovered as the oncogene responsible for FelineMcDonough Sarcoma, is a type III receptor tyrosine kinase that binds to the macrophage or monocyte colony-stimulating factor (M-CSF or CSF-1). Signal transduction through that binding results in survival, proliferation, and differentiation of monocyte/macrophage lineage. Overexpression of CSF-1 and/or FMS has been implicated in a number of disease states such as the growth of metastasis of certain types of cancer, in promoting osteoclast proliferation in bone osteolysis, and many inflammatory disorders. Inhibition of CSF-1 and/or FMS may help treat these pathological conditions. This article reviews FMS gene, FMS kinase, CSF-1, IL-34, and their roles in bone osteolysis, cancer biology, and inflammation. Monoclonal antibodies, FMS crystal structure, and small molecule FMS kinase inhibitors of different chemical scaffolds are also reviewed.
URI
http://pubs.kist.re.kr/handle/201004/45174
ISSN
01986325
Appears in Collections:
KIST Publication > ETC
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE